Wenxue Ma

Title(s)Project Scientist, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
Emailwma@ucsd.edu
ORCID ORCID Icon0000-0001-9228-6162 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California-San Diego, San Diego, CAPostdoc04/2005Cancer Immunotherapy
    University of Wisconsin-Madison, Madison, WIPostdoc08/2004Molecular Immunology
    University of Nebraska Medical Center, Omaha, NEPostdoc08/2002Drug Delivery with Nanotechnology
    Zhejiang University, HangzhouPhD06/2002Immuno-Oncology
    Zhejiang Medical University, HangzhouMD07/1989Clinical Medicine
    Zhejiang Medical University, HangzhouMS07/1997Clinical Oncology
    Collapse Awards and Honors
    Royal Society of Medicine (RSM)2024  - PresFellow Member
    European Science Foundation (ESF)2023  - PresGrant Evaluation Reviewer
    Research Foundation Flanders (FWO)2023  - PresReviewer for Research Grant, Doctoral and Postdoc Fellowships
    Frontiers in Immunology2022  - PresAssociate Editor, Cancer Immunity and Immunotherapy
    Oncology Research2022  - PresGuest Editor & Editorial Board Member
    Oncology Advances2022  - PresEditorial Board Member
    Cancers2022  - 2023Guest Editor
    Huzhou University School of Medicine, China2013  - 2014Dean & Distinguished Professor
    Natural Science Foundation of Zhejiang, China2014  - 2017Identification & application of novel survivin antigenic peptide sequences. PI (LY14H160015)
    Geron Corporation2007  - 2008Induction of telomerase-specific cytotoxic T lymphocytes (Geron/28-1075), PI (WM001)
    American Association for Cancer Research2010  - 2010AACR Scholar-in-Training Award
    International Society for Stem Cell Research2010  - 2010ISSCR Travel Award
    Zhejiang University, China2000  - 2001Outstanding Postgraduate Scholarship
    Zhejiang University, China2000  - 2001Hisun Pharmaceutical Scholarship
    Zhejiang University, China2000  - 2001The First-class Scholarship
    Zhejiang University, China1999  - 2000Tiwu Wang Scholarship

    Collapse Overview 
    Collapse Overview
    I am a Board-Certified Surgical Attending Oncologist with MD and PhD degrees, currently working as the Director of Drug Discovery at the Sanford Stem Cell Institute, University of California, San Diego, California, USA.

    My expertise includes

    🟦 Cancer Immunotherapy: Focused on enhancing immune responses to target cancer cells.

    🟦 Cancer Stem Cells: Identifying markers and developing therapies, such as Notch1 oncogene therapies for leukemia. The ADAR1 p150 isoform is a major contributor to leukemia-initiating cell (LIC) generation in myeloid leukemia. Rebecsinib, a selective small-molecule inhibitor of splicing-mediated ADAR1 activation, inhibits leukemia stem cell (LSC) self-renewal and prolongs survival in humanized LSC mouse models.

    🟦 Nanomedicine: Developing nanotechnology-based drug delivery systems, including peptide delivery advancements.

    Leadership and Editorial Roles

    🟦 Dean and Distinguished Professor at Huhzou University School of Medicine, where I led the teams in significantly promoting the development of Medical and Nursing disciplines and advancing the enrollment of Clinical Medicine from the second to the first tier.

    🟦 Director of Drug Discovery at the Sanford Stem Cell Institute, UC San Diego, pioneering drug discovery in vivo research.

    🟦 Associate Editor for "Frontiers in Immunology" and "Frontiers in Oncology," Guest Editor for "Cancers," and Editorial Board Member for "Oncology Research" and "Oncology Advances." Grant Reviewer for the European Science Foundation (ESF) and the Research Foundation Flanders (FWO), as well as a reviewer for 52 medical science-related journals since 2006.

    Collapse ORNG Applications 
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis. Cytokine Growth Factor Rev. 2024 Aug 24. Yu B, Ma W. PMID: 39191624.
      View in: PubMed   Mentions:    Fields:    
    2. Role of LECT2 in exacerbating atopic dermatitis: insight from in vivo and in vitro models via NF-?B signaling pathway. Front Immunol. 2024; 15:1439367. Liu Z, Jiang X, Zhao K, Ruan H, Ma Y, Ma Y, Zhou Q, Zhang J, Sun X, Ma W, Xu S. PMID: 39206203; PMCID: PMC11349537.
      View in: PubMed   Mentions:
    3. Unleashing the potential of CD39-targeted cancer therapy: Breaking new ground and future prospects. Biomed Pharmacother. 2024 Aug 10; 178:117285. Zhou Q, Shao S, Minev T, Ma W. PMID: 39128190.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    4. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024 Aug 05; 13(1):76. Li J, Chen P, Ma W. PMID: 39103972.
      View in: PubMed   Mentions:
    5. CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Lett. 2024 Aug 10; 597:217072. Xu S, Ma Y, Jiang X, Wang Q, Ma W. PMID: 38885807.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    6. Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy. Cytokine Growth Factor Rev. 2024 04; 76:12-21. Xu S, Wang Q, Ma W. PMID: 38431507.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    7. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci. 2024 Apr; 115(4):1060-1072. Bao Y, Zhang D, Guo H, Ma W. PMID: 38308498; PMCID: PMC11007055.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    8. Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Cell Rep. 2024 Feb 27; 43(2):113704. Rivera M, Zhang H, Pham J, Isquith J, Zhou QJ, Balaian L, Sasik R, Enlund S, Mark A, Ma W, Holm F, Fisch KM, Kuo DJ, Jamieson C, Jiang Q. PMID: 38265938; PMCID: PMC10962356.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    9. Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front Immunol. 2023; 14:1332057. Chen Q, Jia G, Zhang X, Ma W. PMID: 38239350; PMCID: PMC10794487.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance. Cancers (Basel). 2023 Dec 15; 15(24). Yao L, Wang Q, Ma W. PMID: 38136402; PMCID: PMC10742031.
      View in: PubMed   Mentions: 2  
    11. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res. 2023; 32(1):49-60. Chen Q, Guo X, Ma W. PMID: 38188674; PMCID: PMC10767231.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. Game-changing insights on vertebral skeletal stem cells in bone metastasis and therapeutic horizons. Oncol Res. 2023; 32(1):95-98. Chen Q, Zhao X, Ma W. PMID: 38188672; PMCID: PMC10767245.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    13. Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs. Front Immunol. 2023; 14:1295684. Shao S, Miao H, Ma W. PMID: 38035068; PMCID: PMC10682717.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    14. Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. Front Oncol. 2023; 13:1292211. Yao L, Chen J, Ma W. PMID: 37954074; PMCID: PMC10635515.
      View in: PubMed   Mentions: 1  
    15. Malignant A-to-I RNA editing by ADAR1 drives T-cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Res Sq. 2023 Jun 16. Rivera M, Zhang H, Pham J, Isquith J, Zhou QJ, Sasik R, Mark A, Ma W, Holm F, Fisch KM, Kuo DJ, Jamieson C, Jiang Q. PMID: 37398458; PMCID: PMC10312963.
      View in: PubMed   Mentions:
    16. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine. 2023 03 17; 41(12):2073-2083. Lu L, Ma W, Johnson CH, Khan SA, Irwin ML, Pusztai L. PMID: 36813666; PMCID: PMC10064809.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. Cell Stem Cell. 2023 03 02; 30(3):250-263.e6. Crews LA, Ma W, Ladel L, Pham J, Balaian L, Steel SK, Mondala PK, Diep RH, Wu CN, Mason CN, van der Werf I, Oliver I, Reynoso E, Pineda G, Whisenant TC, Wentworth P, La Clair JJ, Jiang Q, Burkart MD, Jamieson CHM. PMID: 36803553; PMCID: PMC10134781.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    18. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers (Basel). 2022 Dec 03; 14(23). Chen Q, Lu L, Ma W. PMID: 36497465; PMCID: PMC9739567.
      View in: PubMed   Mentions: 9  
    19. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Curr Oncol. 2022 07 12; 29(7):4902-4913. Yao L, Jia G, Lu L, Ma W. PMID: 35877249; PMCID: PMC9320700.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    20. Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. Heliyon. 2022 Apr; 8(4):e09302. Yao L, Lu L, Ma W. PMID: 35497026; PMCID: PMC9040416.
      View in: PubMed   Mentions: 5  
    21. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Sci Adv. 2021 08; 7(33). Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Schultz PG, Kim CH, Young TS. PMID: 34380625; PMCID: PMC8357232.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    22. Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell Rep. 2021 01 26; 34(4):108670. Jiang Q, Isquith J, Ladel L, Mark A, Holm F, Mason C, He Y, Mondala P, Oliver I, Pham J, Ma W, Reynoso E, Ali S, Morris IJ, Diep R, Nasamran C, Xu G, Sasik R, Rosenthal SB, Birmingham A, Coso S, Pineda G, Crews L, Donohoe ME, Venter JC, Whisenant T, Mesa RA, Alexandrov LB, Fisch KM, Jamieson C. PMID: 33503434; PMCID: PMC8477897.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    23. Novel Survivin Peptides Screened With Computer Algorithm Induce Cytotoxic T Lymphocytes With Higher Cytotoxic Efficiency to Cancer Cells. Front Mol Biosci. 2020; 7:570003. Chen Q, Jia G, Zhao X, Bao Y, Zhang Y, Ozkan C, Minev B, Ma W. PMID: 33102521; PMCID: PMC7496070.
      View in: PubMed   Mentions: 4  
    24. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Int Immunopharmacol. 2020 Aug; 85:106628. Yao L, Jia G, Lu L, Bao Y, Ma W. PMID: 32474388.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    25. Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses. Drug Deliv Transl Res. 2019 12; 9(6):1095-1105. Chen Q, Bao Y, Burner D, Kaushal S, Zhang Y, Mendoza T, Bouvet M, Ozkan C, Minev B, Ma W. PMID: 31228097.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    26. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223. Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC. PMID: 31427721; PMCID: PMC7297141.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    27. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer. 2019 Apr 25; 19(1):387. Lu L, Huang H, Zhou J, Ma W, Mackay S, Wang Z. PMID: 31023256; PMCID: PMC6482542.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    28. Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. Cancer Cell. 2019 01 14; 35(1):81-94.e7. Jiang Q, Isquith J, Zipeto MA, Diep RH, Pham J, Delos Santos N, Reynoso E, Chau J, Leu H, Lazzari E, Melese E, Ma W, Fang R, Minden M, Morris S, Ren B, Pineda G, Holm F, Jamieson C. PMID: 30612940; PMCID: PMC6333511.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    29. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clin Transl Oncol. 2019 Apr; 21(4):433-442. Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W. PMID: 30218306.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    30. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. Immunology. 2017 11; 152(3):462-471. Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. PMID: 28664991; PMCID: PMC5629434.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    31. Metastasis-Associated Protein 1 Is Involved in Angiogenesis after Transarterial Chemoembolization Treatment. Biomed Res Int. 2017; 2017:6757898. Xue T, Feng W, Yu H, Zhu M, Fei M, Bao Y, Wang X, Ma W, Lv G, Guan J, Chen S. PMID: 28589145; PMCID: PMC5447282.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    32. IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells. Int Immunopharmacol. 2017 Jun; 47:159-165. Shao S, Risch E, Burner D, Lu L, Minev B, Ma W. PMID: 28410529.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    33. Intracellular Delivery of Molecular Cargo Using Cell-Penetrating Peptides and the Combination Strategies. Int J Mol Sci. 2015 Aug 18; 16(8):19518-36. Li H, Tsui TY, Ma W. PMID: 26295227; PMCID: PMC4581311.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    34. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Res Treat. 2015 Jun; 151(3):491-500. Lu L, Zeng H, Gu X, Ma W. PMID: 25957595.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    35. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med. 2014 Oct 03; 12:275. Godebu E, Muldong M, Strasner A, Wu CN, Park SC, Woo JR, Ma W, Liss MA, Hirata T, Raheem O, Cacalano NA, Kulidjian AA, Jamieson CA. PMID: 25278011; PMCID: PMC4192441.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    36. Intracellular delivery of tumor antigenic peptides in biodegradable-polymer adjuvant for enhancing cancer immunotherapy. Curr Med Chem. 2014; 21(21):2357-66. Li H, Ma W. PMID: 25030301.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    37. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013 May; 3(5):564-77. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. PMID: 23471820; PMCID: PMC3651770.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimalsCells
    38. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 07; 12(3):316-28. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. PMID: 23333150; PMCID: PMC3968867.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCells
    39. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012 Aug 14; 22(2):209-21. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT. PMID: 22897851; PMCID: PMC3422504.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansCells
    40. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One. 2012; 7(6):e39725. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. PMID: 22768113; PMCID: PMC3387267.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    41. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine. 2012; 7:1475-87. Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse C, Grotjahn D, Ichim T, Minev B. PMID: 22619507; PMCID: PMC3356185.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    42. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med. 2011 Mar 31; 9:34. Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, Ozkan M, Hayden M, Schroter S, Carrier E, Messmer D, Kumar V, Minev B. PMID: 21450109; PMCID: PMC3078865.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    43. Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res. 2011 Feb; 1(1):43-52. Sharma B, Ma W, Adjei IM, Panyam J, Dimitrijevic S, Labhasetwar V. PMID: 22553503; PMCID: PMC3339849.
      View in: PubMed   Mentions: 14     Fields:    
    44. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92. Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Chut T, Soiffer R, Mitrovich RC, Lowy I, Ball ED. PMID: 20713164; PMCID: PMC2992836.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCellsCTClinical Trials
    45. Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine. 2010 Oct; 6(5):651-61. Clawson C, Huang CT, Futalan D, Seible DM, Saenz R, Larsson M, Ma W, Minev B, Zhang F, Ozkan M, Ozkan C, Esener S, Messmer D. PMID: 20348031; PMCID: PMC2947606.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    46. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. PMID: 20124220; PMCID: PMC2854430.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    47. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour. Eur J Clin Invest. 2008 Dec; 38(12):931-8. Liu WG, Gu WZ, Zhou YB, Tang HF, Li MJ, Ma WX. PMID: 19021718.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):566-575. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR. PMID: 17255279; PMCID: PMC4030524.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    49. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol. 2006 Nov; 18(11):1563-73. Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, Minev B, Schmidt-Wolf IG, Tracey KJ, Chiorazzi N, Messmer D. PMID: 16966494.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    50. A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy. Immunol Lett. 2005 Oct 15; 101(1):71-80. Huang C, Yu H, Wang Q, Yang G, Ma W, Xia D, Chen X, Yi P, Shen F, Zheng H, Cao X. PMID: 15908014.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    51. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol (R Coll Radiol). 2005 Jun; 17(4):258-63. Ma W, Deng Y, Zhou L. PMID: 15997921.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect. Cancer. 2005 Apr 01; 103(7):1519-28. Yi P, Yu H, Ma W, Wang Q, Minev BR. PMID: 15739200.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    53. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004 Nov 01; 112(2):335-40. Sahoo SK, Ma W, Labhasetwar V. PMID: 15352049.
      View in: PubMed   Mentions: 70     Fields:    Translation:Animals
    54. A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol. 2004 May; 24(3):294-301. Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V. PMID: 15114060.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    55. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci. 2004 Feb; 95(2):160-7. Huang C, Yu H, Wang Q, Ma W, Xia D, Yi P, Zhang L, Cao X. PMID: 14965367; PMCID: PMC11159597.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    56. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein. Cancer Immunol Immunother. 2004 Feb; 53(2):118-24. Ma W, Yu H, Wang Q, Bao J, Yan J, Jin H. PMID: 14574492; PMCID: PMC11032846.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    57. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release. 2003 Sep 19; 92(1-2):173-87. Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, Labhasetwar V. PMID: 14499195.
      View in: PubMed   Mentions: 101     Fields:    Translation:Animals
    Wenxue's Networks
    Concepts (297)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (34)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California